Remicade meets Phase III UC endpoints

Johnson & Johnson (JNJ) subsidiary Centocor reported that its Remicade met the primary endpoint of clinical response at week eight in two Phase III trials to treat moderate to severe active ulcerative colitis (UC) in patients who had inadequate responses to conventional therapy. In the double-blind, placebo-controlled, international ACT 1 and ACT 2 trials, clinical response was defined as a combination of Mayo score reductions from baseline of at least 30% and three points and rectal bleeding subscore changes at week eight. ...